Research in contextEvidence before this studyBefore undertaking this study, we searched PubMed, MEDLINE and references from relevant articles on Dlk1 in metabolism and critically evaluated the quality and originality of the methods and results of animal studies and clinical trials. With the exception of a few studies, the overall view has been that Dlk1 acts as an inhibitor of adipogenesis and fat accumulation. Additionally, a few studies have addressed Dlk1\'s role in glucose homeostasis with diverging results.Added value of this studyOur data contradict prior knowledge and suggest that in non-diabetic and otherwise healthy humans, DLK1 associates with increased fat amounts, and independent hereof directly affects the glucose disposal rate. Animal and cell studies confirm this and further suggest that Dlk1 affects glucose homeostasis through an effect on skeletal muscle glucose uptake.Implications of all the available evidenceTogether with prior knowledge, our data underscore a role of Dlk1 in obesity and implications hereof. Our results in specific hold promise for using DLK1 as an early prognostic marker of individuals that may develop type 2 diabetes (T2D), but currently are diagnosed as non-diabetics. Moreover, together with existing Dlk1 knowledge, results herein may be further used to unravel the complex biology underlying T2D and eventually lead to new treatment targets.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Obesity has become one of the major burdens of modern societies and causes numerous complications, including type 2 diabetes (T2D). More efficient anti-obesity strategies seem to require a combination of approaches \[[@bb0005]\], and identification of new drug targets is therefore warranted. Dysregulated expression of imprinted genes is known to exert a marked impact on embryonic growth and development, but exciting new evidence also suggests a postnatal effect where imprinted genes are implicated in human metabolic disorders \[[@bb0010]\]. The Dlk1-Dio3 imprinted gene cluster is localized to mouse chromosome 12 and human chromosome 14. Defects in this cluster are associated with obesity, leanness, insulin resistance, and impaired glucose tolerance and metabolic disorders \[[@bb0010]\]. Delta like non-canonical Notch ligand 1 (Dlk1) is one out of four protein-encoding paternally expressed genes in the Dlk1-Dio3 domain. The DLK1 protein exists in both transmembrane and shed forms, and is highly homologous to the NOTCH-DELTA protein family \[[@bb0015],[@bb0020]\]. However, although others and we have recently shown that DLK1 interacts with NOTCH1, also Notch-independent mechanisms have been described \[[@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045]\]. Indeed, the underlying mechanisms are still unclear, and the proposed functions of DLK1 are diverse and debated. Inhibition of adipogenesis by Dlk1 was already described twenty-five years ago, and Dlk1 has for long been considered as "the preadipocyte marker" \[[@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070]\]. However, it should be emphasized that the majority of evidence for this relies on *in vitro* work obtained in preadipocyte cell lines \[[@bb0055],[@bb0060]\] and only a few rodent studies exist \[[@bb0050],[@bb0065], [@bb0070], [@bb0075], [@bb0080]\]. Remarkably, more recent studies oppose this idea and note that DLK1 may enhance adipocyte differentiation in some cells (mesenchymal C3H10T1/2 cell line) \[[@bb0085]\], or has no effect on adipose-tissue expansion \[[@bb0090]\]. In addition, several clinical studies relating serum DLK1 levels to obesity/fat mass/weight gain show different relationships in humans affected by various diseases \[[@bb0095], [@bb0100], [@bb0105], [@bb0110]\]. Thus, the impact from Dlk1 on *in vivo* obesity remains controversial and even lacks for healthy individuals.

Thus, to clarify whether novel strategies exploiting Dlk1 may be relevant for anti-obesity drug development or metabolic profiling, we set out to delineate by state-of-art scanning techniques whether Dlk1 has a substantial impact on obesity in healthy human individuals, while performing complementary studies in Dlk1 transgenic animals.

2. Research design and methods {#s0025}
==============================

2.1. Approvals {#s0030}
--------------

All human studies were approved by relevant ethical committees and a written informed consent was obtained from every subject at each site \[[@bb0115], [@bb0120], [@bb0125], [@bb0130]\]. The animal study was approved by the Danish Council for Supervision with Experimental Animals (\#2012-15-2934-00313 and \# 2016--15--0201 − 00941).

2.2. Study populations {#s0035}
----------------------

The clinical details on the study subjects from the Swedish cohort have been published previously \[[@bb0115]\]. Briefly, 56 women with a median age of 41.5 (IQR, 12), were subdivided into obese (median BMI: 41.3; IQR, 11.8; *n* = 30) and non-obese (median BMI: 24.1; IQR, 2.78; *n* = 26).

Subjects from one Italian cohort \[[@bb0120],[@bb0130]\] included 35 healthy non-diabetic men with a median age of 47 years (IQR, 15.1) and median BMI of 27.4 (IQR, 4.3), all of whom underwent Magnetic Resonance Imaging (MRI) scans. An extended Italian cohort, examined by Computer Tomography (CT) and with available data on their epicardial fat, consisted of 158 non-diabetic men, with a median age of 62 years (IQR, 18) and a median BMI of 26.5 (IQR, 3.4).

A Danish cohort encompassed 48 healthy non-diabetic men \[[@bb0125]\] with a median age of 68 years (IQR, 9) and a median BMI of 30.0 (IQR, 5.6). Six patients from the initial population of 54 subjects were excluded based on a diabetic MCP-1 value (*n* = 2), DLK1 levels \>100 (ng/mL) (*n* = 1), missing measures (n = 2), and hemolysis in blood sample (n = 1). Dual X-ray absorptiometry (DXA) was used to measure percentage of body fat (*n* = 48) and quantification of visceral and subcutaneous fat was performed by MRI (*n* = 43) \[[@bb0135]\]. Euglycemic hyperinsulinemic clamps (n = 48) were performed as follows \[[@bb0125]\]: Briefly, after a 120-min. Basal tracer equilibration period, insulin (Actrapid; Novo Nordisk, DK) was infused at a rate of 40 mU/m^2^/min. For 180 min leading to physiological hyperinsulinemia at approximately 400 pmol/L in the insulin-stimulated period. Plasma glucose levels were clamped at approximately 5 mmol/L, using a variable infusion rate of 20% glucose based on bedside plasma glucose measurements (ABL800 Flex, Radiometer, DK) every 10--20 min. Mean glucose disposal rate (mg/min/m^2^) at steady state (the last 20 min. of clamp) was taken as an estimate of whole-body insulin sensitivity.

2.3. Animals and diets {#s0040}
----------------------

To account for Dlk1\'s paternal inheritance, we generated and maintained *Dlk1^−/−^* and *Dlk1^+/+^* colonies by homozygous breeding and backcrossed as previously described \[[@bb0140],[@bb0145]\]. Breeding and housing was done under standard conditions with a 12-h light/12-h dark cycle. Animals were fed *ad libitum* with a normal chow (NC; 10% fat, 20% protein, 70% carbohydrate) or with a high-fat diet (HFD; 45% fat, 35% carbohydrate, 20% protein) (Brogaarden, Denmark) and had free access to water. For all animal experiments, age- and sex-matched animals were used as indicated and where relevant (GTT and PET/CT), animal groups were measured in a mixed order.

2.4. Mouse and human plasma measurements {#s0045}
----------------------------------------

Blood from animals was collected from the tail vein, and DLK1 levels were measured using a mouse DLK1 ELISA essentially as previously described \[[@bb0150]\], except that two monoclonal antibodies (CC-5 and CC-11, generated in-house) against mouse DLK1 were used as capture/detection antibodies. Human serum DLK1 was measured as formerly described \[[@bb0155]\]. Plasma levels of Monocyte Chemoattractant Protein-1 (MCP-1) were measured by ELISA as previously reported \[[@bb0160]\]. Glucagon was measured by ELISA as recommended by the manufacturer (Mercodia).

2.5. Glucose tolerance test {#s0050}
---------------------------

A Glucose Tolerance Test (GTT) was performed in *Dlk1^−/−^* and *Dlk1^+/+^* males/females fed HFD or NC. Briefly, animals were fasted for 6 h \[[@bb0165]\], and following an intraperitoneal (i.p.) injection of [d]{.smallcaps}-Glucose (2 g/kg body weight), blood glucose levels were monitored at indicated time points using the One Touch Ultra® system (LifeScan). In an immunoneutralization experiment, *Dlk1^+/+^* animals (*n* = 15) fed HFD for 13 weeks were injected i.p. with a mouse monoclonal antibody (IgG~1,\ k,~ in house) recognizing an epitope on the extracellular part of the mouse DLK1 protein, or with an isotype-matched control antibody (10 μg MAb/g body weight). GTT was performed one and three days after injection.

2.6. Homeostasis model assessment for insulin resistance {#s0055}
--------------------------------------------------------

The homeostasis model assessment method was used to calculate insulin resistance (HOMA-IR), as described by others \[[@bb0170]\] from fasting plasma glucose and insulin levels: HOMA-IR = (FPI × FPG)/22.5, where FPI is the fasting plasma insulin concentration (mU/L) and FPG is the fasting plasma glucose level (mmol/L). Adipo-IR, a measure of adipose tissue insulin resistance \[[@bb0175]\] = Fasting FFAs (mM) × Insulin (pM).

2.7. Body composition (DXA) {#s0060}
---------------------------

Body composition, including total fat mass, was determined by dual energy X-ray absorptiometry (DXA) using the Lunar PIXImus Mouse Densitometer (Wipro GE Healthcare, WI) with the mice under inhalation anesthesia using 2% Isoflurane.

2.8. Small animal positron emission-/computer-tomography (PET/CT) imaging {#s0065}
-------------------------------------------------------------------------

Small-animal PET/CT was performed on a Siemens INVEON multimodality preclinical scanner. Mice (*Dlk1^+/+^ n* = 15, *Dlk1^−/−^ n* = 13) were fasted overnight prior to PET/CT scanning at baseline (day 0) and one day later (day 1). Mice were subcutaneously injected with 75 μl saline or 0.75 U/(Kg body weight) short acting insulin (Humulin, NOVO Nordisk, DK) respectively, 15 min. Before injection of 18F-Fluoro-deoxy-glucose (FDG). Mice were anesthetized (2% isoflurane), and a bolus injection of FDG (day 0 95.5 ± 9.1 MBq; day 1: 91.6 ± 13.4 MBq) was administered *via* a tail vein catheter. Prior to the PET scan a two-bed CT scan was performed for attenuation correction of the PET data and anatomic orientation. CT and PET images were co-registered using a transformation matrix and CT-based attenuation correction was applied to the PET data. The PET data were reconstructed using the Siemens INVEON pre-clinical software and data analysis of the PET/CT fused images was performed with INVEON software version 4.2 (IRW, Siemens). FDG uptake in each volume of interest (VOI) was reported as standardized uptake values (SUV). VOIs of the skeletal limb hind muscles were normalized using brain uptake as a reference tissue that metabolizes glucose independent of insulin.

2.9. *In vitro* cell transfections {#s0070}
----------------------------------

Mouse C2C12 myoblast as well as 3 T3-L1 preadipocytes were cultured as previously described \[[@bb0140],[@bb0180]\]. For plasmid transfection we used vectors expressing the entire DLK1 protein (pLHDLK1-HA), protease site-lacking DLK1 (pLHDLK1ΔP-HA), soluble DLK1 (pLHDLK1E-HA) or empty vector (pLHCX-HA) \[[@bb0185]\]. Plasmids were purified using a QIAGEN Plasmid Miniprep Kit (Qiagen) and the concentration measuered by Nanodrop (Saveen Werner, DK). Purity was evaluated by visualization on a 1% agarose gel. Transfections were performed using electroporation (Amaxa Nucleofector™ Technology, Lonza) at optimal confluence according to the manufacturer\'s instructions. Myoblasts (2.7--3.7 × 10^6^) were suspended in 100 μL of Cell line Mirus Nucleofector solution (Lonza) with two different concentrations of plasmids. Transfected cells reached a 10-fold increase in the expression of DLK1. Cells were analyzed by immunostaining or qPCR. For preadipocytes, siRNA transfections were performed as previously described \[[@bb0180]\].

2.10. qPCR and mRNA arrays {#s0075}
--------------------------

Total RNA extraction and qPCR analysis were performed as previously described \[[@bb0140]\]. Relative expression levels were obtained after normalizing the raw data against multiple endogenous control genes as determined by the qBase^+^ platform (Biogazelle). In the Swedish cohort, total RNA was isolated from subcutaneous abdominal adipose tissue biopsies. Biotinylated complementary RNA was subsequently analyzed using the GeneChip Human Gene 1.0 ST Array (Affymetrix Inc., Santa Clara, CA) and standardized protocols as described previously \[[@bb0115]\]. Data are deposited at the National Center for Biotechnology Information Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) under the accession number GSE25402.

2.11. Adipocyte size quantification and Immuno(cyto/histo)chemistry {#s0080}
-------------------------------------------------------------------

Average adipocyte volume (pL) was determined using HE-stained sections of formaldehyde fixed (FFPE) gonadal adipose tissue obtained from six week-old *Dlk1^+/+^* (*n* = 12), *Dlk1^−/−^* (n = 12) mice fed NC or HFD for 28 weeks before being sacrificed. Two sections (each comprising five fields) from each animal were used for quantification. Images were acquired using a Leica DMI4000B Cool Fluo Package instrument equipped with a Leica DFC340 FX Digital Camera and analyzed using ImageJ 1.48 software with MRI adipocyte size tool. Average adipocyte volume was calculated from the Feret\'s diameter values. Immunohistochemistry of FFPE tissues was performed as previously described \[[@bb0140]\] with rabbit anti-mouse DLK1 (1:2000; in-house) \[[@bb0150]\] or, rabbit anti-Glut4 (1:1000; ab33780, Abcam) antibodies. Secondary antibodies used were Alexa 555- or 488-conjugated donkey anti-IgG (1:200, Molecular Probes), and mounting medium contained DAPI (Vectashield, Vector Labs). Images were captured using a Leica DMI4000B instrument equipped with a Leica DFC340 FX Digital Camera. Exposure and picture processing were applied equally to m.gastrocnemius sample sections and controls. GLUT 4 protein expression differed within all specimens with some areas showing high membrane appearance, whereas others showing much less membrane GLUT4 localization. To minimize subjectivity in GLUT4 quantification, a picture was acquired for all cross-sectional areas (high and low) in a given specimen. Analysis was performed using the ImageJ software, where ROIs were used to remove areas such as large vessels and mesenchyme. For each specimen, two averages of the mean intensity were calculated for high- (*n* = 6) and low (*n* = 4--6, 3 specimens did not include low intensity areas of cross section) intensity areas, and a final average (high and low (n = 4--6)) of the entire section was calculated.

2.12. Statistical analyses {#s0085}
--------------------------

The statistical significance of the difference between means was determined by either two-tailed *t*-tests, or by one- or two-way ANOVA followed by appropriate post-hoc tests as indicated. Clinical values were presented using the median and interquartile range (IQR). Associations between DLK1 and clinical parameters of interest were evaluated by correlation analysis using Spearman\'s rank correlation coefficient or the Pearson correlation coefficient as appropriate. Six observations were removed from the data set for various reasons (diabetic MCP, lacking measures, hemolysis, or DLK1 outlier). A mediation analysis was performed to investigate how age, BMI, and fat percentage affect the relation between DLK1 and GDR. The mediating process includes the dependent variable GDR, the independent variable DLK1, and the mediators age, BMI, and fat percentage. The mediators BMI and fat percentage are relatively strongly correlated (*r* = 0.7) but removing each of these mediators in turn from the model does not affect the estimation and significance tests substantially. The maximum variance inflation factor among DLK1, age, BMI, and fat percentage is 2.93, so there is no evidence of severe multicollinearity. Finally, in order to improve homogeneity of variances, a logarithmic transformation was applied to GDR (Supplemental Table S1). However, since the two mediation analyses are in substantial agreement, we interpret the results from the analysis based on untransformed data. For statistical analysis, we used GraphPad Prism and the R software environment (version 3.5.1).

3. Results {#s0090}
==========

3.1. DLK1 is associated with increased body fat in humans {#s0095}
---------------------------------------------------------

Circulating DLK1 levels were measured in blood samples from healthy to slightly overweight, non-diabetic Danish men (68 years (9) (median; IQR); *n* = 52) with a median BMI of 29.8 (5.4)) \[[@bb0135]\]. The median concentration of serum DLK1 was 36.15 ng/ml (17.2) and correlated positively with BMI ([Fig. 1](#f0005){ref-type="fig"}a) as also previously shown \[[@bb0095]\]. As determined by Magnetic Resonance Imaging (MRI) ([Fig. 1](#f0005){ref-type="fig"}b-f), the absolute amount of fat as well as the percentage of fat increased significantly with increasing levels of circulating DLK1 in these non-diabetic individuals ([Fig. 1](#f0005){ref-type="fig"}b-c). The relative amount of abdominal fat is in general associated with an increased risk of developing metabolic syndrome. We found that increased levels of circulating DLK1 were associated to increased amounts of central fat mass ([Fig. 1](#f0005){ref-type="fig"}d), and this seemed to be a consequence of increased amounts of visceral-, but not subcutaneous fat ([Fig. 1](#f0005){ref-type="fig"}e-f). Increased epicardial fat is also a marker of the metabolic syndrome \[[@bb0190]\]. In a population of 158 healthy, non-diabetic middle-aged Italian men (median age: 58 years (21 (IQR) and median BMI: 26.8 (3.7)) undergoing CT scans \[[@bb0120],[@bb0130]\], the median concentration of serum DLK1 was 28.9 ng/ml (17.1) and correlated positively with BMI (*p* = .0068; Spearman\'s *r* = 0.2143). In this population, the amount of epicardial fat was significantly associated with DLK1 levels ([Fig. 1](#f0005){ref-type="fig"}g) further supporting a possible link between DLK1 and increased fat in humans, as well as with the development of the metabolic syndrome. No significant correlations were observed between DLK1 and visceral or subcutaneous fat amounts ([Fig. 1](#f0005){ref-type="fig"}h-i) in this population, but these latter data may be undermined by a low power (*N* = 35; see methods) of the subpopulation undergoing whole body scan.Fig. 1DLK1 levels correlate with fat accumulation in humans. (a-f) Correlation analysis of circulating DLK1 in a Danish male cohort (*n* = 48, median age 68 years, IQR 9; median BMI 29.8, IQR 5.5), with (a) BMI, (b) Total fat (kg), (c) Percentage of fat, (d) Central fat mass (kg), (e) Visceral fat mass (arbitrary unit (AU) = pixels\*10^−3^), (f) subcutaneous fat mass (AU). (g-i) Correlation analysis of circulating DLK1 in an Italian cohort (*n* = 158) consisting of non-diabetic men median age: 58 years IQR 21 and median BMI: 26.8, IQR 3.7, with (g) Epicardial fat amount, and for a subpopulation of *n* = 35 (median age 47 years, IQR 15.1; median BMI 27.4, IQR, 4.3) (h) Visceral fat mass (kg) and (i) subcutaneous fat mass (kg). Data were analyzed using Spearman and Pearson correlation analysis, as appropriate. Trend lines imply visual aid and not causality.Fig. 1

Together, these data suggest that in normal to overweight non-diabetic human subjects, DLK1 levels are associated with increased body fat, thus contradicting that DLK1 acts as an adipogenic inhibitor exclusively.

3.2. *Dlk1* deficiency protects against diet-induced obesity in mice {#s0100}
--------------------------------------------------------------------

To directly investigate our positive correlations between increased DLK1 and body fat content we used a *Dlk1^−/−^* mouse strain, which has been used by several research groups in growth-related studies \[[@bb0140]\]. Adult *Dlk1^−/−^* mice were completely negative for Dlk1 in all examined tissues, whereas *Dlk1^+/+^* mice expressed Dlk1 in specific tissues, mainly of neuro-endocrine function (Supplemental Fig. S1).

As an accepted model for the induction of obesity, we compared *Dlk1^+/+^* and *Dlk1^−/−^* mice fed a normal chow (NC) or a high-fat diet (HFD) starting at the age of 6 weeks (= puberty in mice) ([Fig. 2](#f0010){ref-type="fig"}a-c). In both females and males, and irrespective of diet, we found that the weight of *Dlk1^−/−^* mice was significantly reduced as compared to that of *Dlk1^+/+^* control mice ([Fig. 2](#f0010){ref-type="fig"}a). Yet, the percentage of weight gain on NC and HFD was similar in both genotypes (Supplemental Fig. S2), which is in agreement with previous observations that food intake is unaffected by Dlk1 \[[@bb0075],[@bb0090],[@bb0195]\]. To obtain accurate fat content measures in these mice, we used DXA scanning ([Fig. 2](#f0010){ref-type="fig"}b). On NC diet, the fat percentage was slightly increased in *Dlk1^−/−^* as compared to *Dlk1^+/+^* at NC in both females and males ([Fig. 2](#f0010){ref-type="fig"}b-c), a result which was consistent with previous data suggesting that Dlk1 negatively affects adipogenesis \[[@bb0015],[@bb0065],[@bb0200]\]. However, whereas *Dlk1^+/+^* animals substantially increased their fat percentage upon HFD diet, *Dlk1^−/−^* animals were resistant upon HFD and exhibited a fat percentage similar to their NC fed controls ([Fig. 2](#f0010){ref-type="fig"}b-c).Fig. 2*Dlk1*^*−/−*^ mice weigh less than *Dlk1*^*+/+*^ mice regardless of the type of diet, and are resistant to HFD induced obesity. Six-week-old (a-c) and 16-week-old (d-f) *Dlk1*^*+/+*^ and *Dlk1*^*−/−*^ mice were fed normal chow (NC) or high-fat diet (HFD, Altromin, 42% fat). Body weight was determined every week (a, d) and DXA scanning (diet age: 23 weeks; b-c and e-f) was performed to quantify percentage of body fat. Statistical difference was tested by a two-way ANOVA followed by Fisher\'s LSD test; \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, \*\*\*\**P* \< .0001, ns (not significant).Fig. 2

Previous studies performed in mice have shown that Dlk1 inhibits adipocyte enlargement during obesity \[[@bb0065], [@bb0070], [@bb0075]\]. We found that *Dlk1^+/+^* animals independently of sex, exhibited an expected increase in fat cell volume upon HFD whereas *Dlk1^−/−^* animals showed no change, despite having slightly larger adipocytes on NC diet as compared to *Dlk1^+/+^* animals (Supplemental Fig. S3). Furthermore, we did not find a negative association between *DLK1* mRNA and fat cell size in WAT subcutaneous biopsies obtained from normal to overweight human subjects (Supplemental Fig. S3).

Since adipose tissue develops during the postnatal and juvenile life \[[@bb0205]\], the results of an early postnatal HFD feeding protocol as tested above may have influenced fat tissue development by itself. Thus, we next tested whether the absence of *Dlk1* affected fat expansion in adult animals by starting the diet intervention at the age of 16 weeks. In contrast to the findings in juvenile animals ([Fig. 2](#f0010){ref-type="fig"}a), the difference in body weight between genotypes in NC fed mice, particularly in females, were no longer evident ([Fig. 2](#f0010){ref-type="fig"}d). For *Dlk1^−/−^* females on HFD, this resulted in a substantially lower weight gain (Supplemental Fig. S2). As for the juvenile animals, DXA scanning showed a slightly increased fat percentage at basal levels in *Dlk1^−/−^ versus Dlk1^+/+^* animals ([Fig. 2](#f0010){ref-type="fig"}e-f). Yet, an increase in % fat was still highly substantial for *Dlk1^+/+^* animals on HFD induction, with only a modest effect in *Dlk1^−/−^* female animals and none in males ([Fig. 2](#f0010){ref-type="fig"}e-f). Together these animal studies demonstrate that irrespective of obesity onset, mice lacking *Dlk1* are protected from HFD-induced obesity, although they may have slightly more adipose tissue under isocaloric conditions. Thus, these data supports our human data showing a positive association between DLK1 and fat masses.

3.3. DLK1 has a direct negative impact on glucose homeostasis {#s0105}
-------------------------------------------------------------

Since our data revealed that a lack of Dlk1 protects against diet-induced obesity, we next hypothesized that it would also protect against impaired glucose tolerance as induced by HFD. Except for adult males, all animals on HFD displayed higher fasting blood glucose levels than their NC-fed controls (Supplemental Fig. S4). This was independent of genotype, sex or age at onset (6- or 16-weeks of age) of diet-induced obesity (Supplemental Fig. S4) and verified that HFD resulted in insulin resistance. As expected, blood glucose was significantly higher in the adult animal group compared to the juvenile (Supplemental Fig. S4), reflecting that increasing age lead to decreased insulin sensitivity. However, neither genotype nor sex influenced these results, suggesting that *Dlk1* does not have an impact on the normal age-related negative changes in glucose homeostasis as such.

We next subjected our animals to glucose tolerance tests (GTT) ([Fig. 3](#f0015){ref-type="fig"}a-b). Overall, GTT profiles ([Fig. 3](#f0015){ref-type="fig"}a-b) reflected that females responded to HFD by a greater reduction in glucose tolerance than males. This is in agreement with the fat percentage profiles described above ([Fig. 2](#f0010){ref-type="fig"}c, f) and as also noticed by others it underscores the importance of sex, at least in mouse \[[@bb0210],[@bb0215]\]. However, while impairment of glucose clearance was obvious in juvenile *Dlk1^+/+^* females the *Dlk1^−/−^* animals were protected against glucose intolerance ([Fig. 3](#f0015){ref-type="fig"}a). This phenotype was, however, attenuated in adult animals where the ability to clear glucose was similar in both genotypes independent of sex ([Fig. 3](#f0015){ref-type="fig"}b). Suppressing the bioavailable DLK1 levels *in vivo* by 73% (Supplemental Fig. S5) with an antibody in juvenile *Dlk1^+/+^* females on HFD did not result in any acute changes in blood glucose clearance (Supplemental Fig. S5). Notably, while fasting glucose levels were unaffected by genotype (Supplemental Fig. S4) fasting insulin levels were significantly lower in *Dlk1^−/−^* animals as compared to *Dlk1^+/+^* controls, leading to reduced HOMA-IR levels ([Fig. 3](#f0015){ref-type="fig"}c), an estimate of insulin resistance based on fasting levels of glucose and insulin.Fig. 3Lack of *Dlk1* improves glucose homeostasis in female mice. (a, c (Top)) Six-week-old or (b, c (Bottom)) 16-week-old *Dlk1*^*+/+*^ or *Dlk1*^*−/−*^ mice were fed normal chow (NC) or high-fat diet (HFD) for 25 weeks. Glucose tolerance tests (GTT) were performed at the end of the experiment and fasting insulin and glucose levels (Supplemental Fig. S4) were measured to calculate the HOMA-IR index. For A-B, the area under the curve (AUC) was calculated for each mouse and used for statistical testing. a-c statistical difference was tested by a two-way ANOVA followed by Fisher\'s LSD test; \**P* \< .05, \*\**P* \< .01, ns (not significant).Fig. 3

Thus, in agreement with the above data, where *Dlk1* enhanced obesity, it similarly has a negative impact on insulin sensitivity.

To extend these data into humans, we analyzed whole body insulin sensitivity by the gold standard technique, the euglycaemic hyperinsulinaemic clamp, in relation to serum DLK1 levels. Indeed, serum DLK1 is negatively correlated with glucose disposal rates (GDR) measured in 48 (68 year-old (9); median BMI: 30.0 (5.6)) of the 58 previously described Danish men ([Fig. 4](#f0020){ref-type="fig"}a). Importantly, there is no evidence of mediation of the effect of DLK1 by age, BMI, or fat percentage ([Fig. 4](#f0020){ref-type="fig"}b-c and Supplemental Table S1). The direct effect from DLK1 to GDR is statistically significant (*p* = .007). None of the three indirect effects explaining the extent to which the effect of DLK1 is mediated by age, BMI, and fat percentage, respectively, are statistically significant at the 0.05 significance level. The total effect is highly statistically significant (*p* \< .001).Fig. 4Dlk1 is related to an adverse metabolic profile connected with insulin resistance in humans. Spearman correlation analysis of circulating DLK1 in 48 men (68-year-old, IQR 9; median BMI 30, IQR 5.6) from a Danish cohort with (a) glucose disposal rate. (b) Path diagram of the multiple-mediator model. The direct effect from DLK1 to GDR is labeled c. The effects from DLK1 to age, BMI, and fat percentage are labeled a1, a2, and a3, respectively. The effects from age, BMI, and fat percentage to GDR are labeled b1, b2, and b3, respectively. The three indirect effects explaining the extent to which the effect of DLK1 is mediated by age, BMI, and fat percentage are given by the products a1 · b1, a2 · b2, and a3 · b3, respectively. The total effect is given by the sum of direct and indirect effects: c + (a1 · b1) + (a2 · b2) + (a3 · b3). Dependent variable: GDR. Independent variable: DLK1. Mediators: Age, BMI, and fat percentage. (c) Summary of the mediation analysis. Estimates, standard errors, *z*-values, *p*-values, and 95% lower and upper confidence bounds (LCB and UCB, respectively). Bootstrapping with 5000 draws was used to estimate the standard errors. (d-f) Spearman correlation analysis in the Danish cohort of circulating DLK1 and (d) HOMA-IR, (e) Adipo-IR, and (f) MCP-1. Spearman correlation analysis of circulating DLK1 in an Italian cohort of men (*n* = 157; median age: 58 years, IQR 21; median BMI 26.8, IQR 3.7) with (g) HOMA-IR, (h) Adipo-IR, and (i) MCP-1. Trend lines imply visual aid and not causality.Fig. 4

Moreover, serum DLK1 was positively correlated with HOMA-IR and Adipo-IR \[[@bb0175]\] ([Fig. 4](#f0020){ref-type="fig"}d-e), the latter indicating that insulin resistance in adipose tissue may also be affected by Dlk1 and contribute to the reduction of whole-body insulin sensitivity. As noted above, the examined cohorts herein were not established type 2 diabetics and had relatively low levels of the inflammation marker MCP-1 which did not correlate with DLK1 levels ([Fig. 4](#f0020){ref-type="fig"}f). Similar results were observed in the case of the Italian cohort ([Fig. 4](#f0020){ref-type="fig"}g-i). These data thus extend our animal results into healthy, non-diabetic humans and indicate that Dlk1 has a direct effect on glucose disposal, and that plasma DLK1 may be an early predictor of insulin resistance and TD2 in healthy humans (at least in men) well before the onset of an MCP-1 increase.

3.4. Dlk1 impacts glucose homeostasis upon diet-induced obesity, through regulation of glucose uptake in skeletal muscle {#s0110}
------------------------------------------------------------------------------------------------------------------------

We finally assessed whether our results could be explained by DLK1 mediating inhibition of gluconeogenesis in the liver or by inhibition of skeletal muscle glucose uptake. Measuring the level of glucagon in the NC and HFD treated juvenile female animals showed an increase upon HFD, but it did not reveal any apparent difference between genotypes (Supplemental Fig. S6). This supports that fasting glucose levels are similar between genotypes (Supplemental Fig. S4), and indicates that gluconeogenesis is unaffected in *Dlk1^−/−^* animals, and therefore not responsible for the observed resistance to obesity-induced insulin resistance ([Fig. 2](#f0010){ref-type="fig"}). In agreement, hepatic glucose production in the population of Danish men did not correlate to DLK1 levels at neither basal nor clamp conditions (Supplemental Fig. S6).

We then tested glucose uptake in skeletal muscle directly by using ^18^F-FDG PET/CT-scanning ([Fig. 5](#f0025){ref-type="fig"}a). For this study, female *Dlk1^+/+^* and *Dlk1^−/−^* mice were fed short-term (6 weeks *versus* 25 and 28 weeks used above, respectively) with NC or HFD, starting at 3 weeks, which has been shown applicable to induce glucose intolerance by others \[[@bb0220]\]. The standardized ^18^F-FDG uptake values (SUVs) for each animal (skeletal hind limb muscle *vs.* brain) were similar to those described by others \[[@bb0225]\], and all animals responded well to insulin treatment with an enhanced FDG uptake ([Fig. 5](#f0025){ref-type="fig"}b-c). Most interestingly, *Dlk1^−/−^* mice responded to the short duration of high calorie intake by increasing their skeletal muscle glucose uptake significantly ([Fig. 5](#f0025){ref-type="fig"}b), supporting a higher ability for body glucose clearance as observed above ([Fig. 3](#f0015){ref-type="fig"}a). In contrast, *Dlk1^+/+^* animals were unaffected in their glucose uptake ability by this short-term HFD ([Fig. 5](#f0025){ref-type="fig"}b). At the molecular level, we found that expression of the major glucose transporter *Glut4* was increased in *Dlk1^−/−^* animals as compared with *Dlk1^+/+^* controls ([Fig. 5](#f0025){ref-type="fig"}d), which was verified at the protein level ([Fig. 5](#f0025){ref-type="fig"}e-f) using GLUT4 immunohistochemical quantification as exploited by others \[[@bb0230], [@bb0235], [@bb0240], [@bb0245], [@bb0250]\].Fig. 5Lack of *Dlk1* improves skeletal muscle glucose uptake. (a-c) Three-week-old *Dlk1*^*+/+*^ and *Dlk1*^*−/−*^ female mice were fed NC or HFD short-term for 6 weeks and subjected twice (± insulin) to PET/CT scanning for determination of skeletal muscle glucose (^18^F-FDG) uptake. (a) Fields used for quantification are marked by arrows (Yellow: Skeletal muscle; Blue: Brain). (b-c) For each mouse, ^18^F-FDG standardized uptake value (SUV) for skeletal muscle was normalized to the brain SUV, and statistical difference was tested by a two-way ANOVA followed by Fisher\'s LSD test. (d-f) Six-week-old female *Dlk1*^*+/+*^ and *Dlk1*^*−/−*^ mice were fed normal chow (NC) or high-fat diet (HFD) long-term (28 weeks), and (d) *Glut4* (*Slc2a4*) mRNA levels were determined in hind limb (m. Gastrocnemius) skeletal muscles using qPCR and (e-f) verified by GLUT4 quantification in immunohistochemical stainings. For qPCR, raw data were normalized against *Gapdh* and *beta-actin* (qBASE- M:0.390; CV:0.137). For GLUT 4 IHC staining, mean intensity GLUT4 fluorescence was quantified in areas of both low and high GLUT4 to minimize subjectivity (see materials and methods for details), and an overall average was calculated for each animal in (F). Statistical difference was tested by a two-way ANOVA followed by Fisher\'s LSD test. \*P \< .05, \*\*P \< .01, \*\*\**P* \< .001, \*\*\*\*P \< .0001, ns (not significant). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 5

3.5. *Dlk1* negatively regulates expression of Glut4-the major glucose transporter {#s0115}
----------------------------------------------------------------------------------

To confirm Dlk1s impact on Glut4 expression, we transfected skeletal myoblasts with different Dlk1 expression constructs and differentiated the cells into multinucleated myotubes ([Fig. 6](#f0030){ref-type="fig"}a). However, only a minor fraction of myotubes expressed DLK1 ([Fig. 6](#f0030){ref-type="fig"}b), and thus disabled further *Glut4* evaluation. As an alternative, non-differentiated myoblasts showed a transfection efficiency of 40% (data not shown), and although they express *Glut 4* at lower levels than myotubes, we attempted to evaluate *Glut4* expression in these cells. Despite the limitations, indeed we did find *Glut4* to be decreased in Dlk1-transfected cultures as compared to cultures transfected with empty vector ([Fig. 6](#f0030){ref-type="fig"}c), and this was further aggravated when DLK1 overexpression was increased up to 10-fold ([Fig. 6](#f0030){ref-type="fig"}d). Furthermore, we found that differentiated preadipocytes that are easily transfected and express high amounts of endogenous DLK1, substantially increased their *Glut4* expression upon siRNA mediated knock-down of *Dlk1* ([Fig. 6](#f0030){ref-type="fig"}e). Together, this points to Dlk1 as a regulator of GLUT4 mediated glucose uptake and may at least partially explain why HFD-fed *Dlk1^−/−^* animals are less obese and insulin resistant as compared with *Dlk1^+/+^* mice.Fig. 6*In vitro* Dlk1 overexpression and knock-down inhibits and enhances Glut4 expression, respectively. (a) Myoblasts were differentiated into multinucleated myofibers and transfected with empty vector and different Dlk1 constructs (full-length (FL), lacking the protease recognition site (ΔP) and the extracellular soluble domain (S) before DLK1/MYOSIN/DAPI staining and (b) quantification of percentage DLK1 positive myofibers. (c-d) Myoblasts were transfected with empty vector and Dlk1 constructs as above, but at two different concentrations before qPCR. (e) Dlk1 expression 3 T3-L1 preadipocytes that were transfected with siRNA-Scramble, or siRNAs against all Dlk1 isoforms (Dlk1Total) or Dlk1 isoforms containing the protease site (Dlk1PS) before differentiation and qPCR. For c-e, qPCR raw data were normalized against multiple stably expressed control genes as determined by the Qbase-plus platform. Statistical difference was tested by a one-way ANOVA followed by Fisher\'s LSD test. \*P \< .05, \*\*P \< .01, \*\*\*P \< .001, \*\*\*\**P* \< .0001.Fig. 6

4. Discussion {#s0120}
=============

Our data clearly demonstrate that *Dlk1* is not an inhibitor of *in vivo* fat tissue mass in healthy to overweight humans or mice, although it may exert a slightly inhibiting role on adipogenesis during development leading to a modest increase in fat mass accumulation as previously considered by others and us hereto \[[@bb0015],[@bb0050],[@bb0055],[@bb0065],[@bb0075],[@bb0095],[@bb0105],[@bb0180]\]. On the contrary, Dlk1 is associated with increased obesity. Moreover, we found that Dlk1 has a negative and direct impact on whole body glucose homeostasis upon obesity, by regulating GLUT4 mediated skeletal muscle glucose uptake. This supports the idea that imprinted genes play an important role in metabolism after birth \[[@bb0010]\], and may serve as key targets for new interventions.

Specifically, in this study we demonstrate that absence of *Dlk1* is not permissive for fat accumulation in young or adult mice, and that *Dlk1^−/−^* mice after an HFD diet indeed are resistant to obesity, as compared to *Dlk1^+/+^* animals. Thus, in times of excess dietary lipids, Dlk1 somehow mediates lipid storage. This could be due to a direct effect from Dlk1 on fat tissue or an indirect effect *e.g.* on insulin secretion in the pancreas.

Our data are in agreement with a recent developmental study conducted by the Sul\'s group, in which ablation of *Dlk1* at E10.5 or P1-P21 reduced WAT development dramatically \[[@bb0050]\], thus contradicting their earlier papers where *Dlk1*-null mice have been reported to be more obese \[[@bb0065]\] and *Dlk1*-overexpressing mice to be less obese \[[@bb0070],[@bb0075]\]. Also a recent study by Ferguson\'s group briefly noted that overexpression of *Dlk1* in the adult (24-weeks) hyperphagic *ob/ob* mouse did not negatively alter body fat percentage \[[@bb0090]\]. Herein, we furthermore evaluate in humans, which reconciles that Dlk1 is positively associated with obesity, and the perception of Dlk1 being an adipogenic inhibitor should be changed. Technical issues may explain some of the reported diversity. For instance, weighing the individual fat pads as done previously \[[@bb0070],[@bb0075],[@bb0090]\] may be a questionable measurement of changes in body fat if not normalized to body weight; a parameter that is always found to be affected by Dlk1. Indeed, Schmidt and co-workers pointed out that the fat pad weight when expressed as percentage of body weight, was decreased in Dlk1-null female, but not male animals \[[@bb0255]\], which is in agreement with our data. In the present study we overcome the issue of weighing fat pads by using DXA and MRI scanning to measure body fat in animals and humans. Moreover, the previously published studies overexpressing DLK1 in transgenic mice were based on a fusion protein consisting of two DLK1 extracellular domains fused with the Fc-part of a human immunoglobulin. Such a structure is dissimilar from physiological DLK1 and may explain differences \[[@bb0070],[@bb0075]\]. Likewise, the two existing *Dlk1*^*−/−*^ mouse strains generated by the Sul \[[@bb0065]\] and the Laborda \[[@bb0145]\] (used herein) groups differ with respect to Dlk1 gene disruption strategy, which may potentially explain the differences in phenotype. Nevertheless, the animal data herein is strikingly supportive of the human data where Dlk1 associates positively with obesity and not *vice versa*. Likewise, in clinical studies, the discrepancies between Dlk1 being a positive mediator of obesity in our healthy individuals and other studies considering it as an obesity guard \[[@bb0100], [@bb0105], [@bb0110]\] may be explained by age, gender, and especially the health status of included subjects. In regard to the latter, we alone use healthy non-diabetic individuals whereas others either compare groups of diseased and healthy individuals, solely diseased individuals or use a mixture of healthy and diseased individuals for their correlations. Moreover, the choice of assay technology is also likely to influence the outcome and herein we have used a DLK1 ELISA that is well characterized and based on high affinity DLK1 antibodies \[[@bb0155]\] whereas most other studies have used commercially available kits. Yet, the underlying mechanism of DLK1 associating with increased amounts of adipose tissue is still unclear. Our animal study suggests that when dietary fats are in excess, Dlk1 mediates lipid storage as visualized by increased fat deposits and fat cell hypertrophy. From previous studies by us and others, we know that the number of DLK1+ cells in fat is discrete, and mainly refers to cells of the vascular lineage \[[@bb0260],[@bb0265]\]. A lack of correlation between DLK1 mRNA and fat cell size in humans indicates that any direct effect of such DLK1+ residing cells would be regulated at the post-transcriptional level. However, herein it seems more likely that either the soluble circulating DLK1 affects lipid storage directly or alternatively, that DLK1 present in the pancreatic beta cells somehow mediates insulin secretion thereby indirectly stimulating fat accumulation in adipose tissue.

In humans, we observe by the gold-standard euglycaemic hyperinsulinaemic clamp a negative impact of DLK1 on insulin sensitivity, with glucose disposal rates being negatively correlated with circulating DLK1 levels. Our data thus firmly establish DLK1´s role in glucose metabolism in healthy subjects where it is intriguing to speculate that circulating DLK1 may predict a pre-diabetic phenotype as discussed below. Our results with the healthy non-diabetic cohorts supports previous studies correlating DLK1 positively to insulin resistance in non-healthy or mixed (healthy/non-healthy) cohorts \[[@bb0070],[@bb0095],[@bb0100],[@bb0270],[@bb0275]\]. Interestingly, using similar or alternative approaches other groups have shown the opposite \[[@bb0090],[@bb0110],[@bb0200],[@bb0280]\] or no association \[[@bb0285]\]. Of these, Flehmig and co-workers \[[@bb0280]\] used a distance-based hierarchical cluster analysis approach to find patterns between serum adipokine levels and clinical parameters related to obesity, inflammation and glucose metabolism. In their moderate to severely obese cohort, DLK1 segregated into an insulin resistance/hyperglycemia cluster rather than an obesity cluster but DLK1 levels were found to be significantly lower in individuals with T2D than without. So, while several studies reach the same general conclusion that DLK1 has an impact on glucose metabolism, the underlying data are surprisingly very different. This can possibly be ascribed to differences in study populations (and species) and/or the use of different assays for DLK1 quantification as stated above. Independent of DLK1 assay technology however our data herein support previous studies on Dlk1 overexpressing mice where Villena et al. reported attenuation of insulin sensitivity by DLK1 during an euglycaemic hyperinsulinaemic clamp although they observed Dlk1 to negatively affect obesity \[[@bb0075]\]. Likewise, Abdallah et al. showed that insulin sensitivity is improved by the absence of *Dlk1* ^55^. In our human cohort, a mediation analysis revealed that the effect of Dlk1 on glucose disposal in healthy individuals is not mediated by age, BMI, or fat percentage. Although we did not observe any effect from Dlk1 on glucagon levels and fasting glucose levels in animals nor any correlations between DLK1 and hepatic glucose production in humans, we cannot exclude that in another context, such as prolonged fasting, Dlk1 could be implicated in gluconeogenesis as reported in mice \[[@bb0200]\]. Yet, our data more likely suggest that Dlk1 impacts glucose homeostasis by inhibiting *in vivo* glucose uptake in skeletal muscle through regulation of the glucose transport machinery. Our GLUT 4 immunohistochemical staining profile agrees with that observed by others in the field \[[@bb0230], [@bb0235], [@bb0240], [@bb0245], [@bb0250]\] and reflect our *Glut4* mRNA data, which underscore that Dlk1 affects Glut4 regulation. Moreover, we confirmed this independently in two different cell lines, with two distinct gene manipulation strategies. This suggests that the *in vivo* Dlk1 phenotype on glucose homeostasis cannot solely be explained by Dlk1 impacting muscle growth during development. This is further supported by our relative skeletal muscle/brain ^18^F-FDG PET/CT glucose uptake experiments, which are independent on muscle size. Yet, since DLK1 expression is very low in normal adult skeletal muscle, it will be interesting to see whether the observed Glut4 regulation is mediated by soluble DLK1 \[[@bb0070]\] working as a hormone and part of a novel feedback axis within glucose homeostasis. Alternatively, Dlk1\'s effect could also be mediated by insulin and its regulation of GLUT4 translocation. Our short-term *in vivo* anti-DLK1 strategy did not result in any acute changes in glucose levels, which may suggest that the phenotype is due to more chronic changes or that the organ responsible for the DLK1 fraction mediating insulin resistance is not reached by the anti-DLK1 strategy. We have previously noted that antibody-based *in vivo* neutralization of DLK1 triggers an unknown compensatory feedback loop \[[@bb0290]\] and our unpublished data show that long-term anti-DLK1 targeting through the circulation indeed increases circulating DLK1 when treatment stops. Currently, we can only speculate on the underlying mechanism, yet in a treatment perspective that seeks minimal side effects, the major source of circulating DLK1 in this feedback loop needs to be pinpointed and may help further clarify the potential of targeting DLK1 *in vivo* in relation to preventing/treating T2D. Moreover, recent work by others has demonstrated that the NOTCH pathway is implicated in metabolism and it is likely that the observed effect of Dlk1 on the glucose machinery is mediated by a NOTCH-dependent mechanism.

In perspective, it will also be of interest to see, in a longitudinal human study, whether increased Dlk1 levels indeed predispose for developing the metabolic syndrome later in life. In this regard, it is noteworthy that increased levels of circulating DLK1 in our study were associated with decreased glucose disposal rates in subjects with no diagnosed insulin resistance. The pro-inflammatory chemokine MCP-1 (CCL2) has been linked to obesity and insulin resistance for many years and the general notion hitherto is that elevated MCP-1 levels precede the inflammatory processes that eventually lead to insulin resistance \[[@bb0295]\]. Whereas others report 195 and 224 pg/mL MCP-1 levels for individuals with impaired glucose tolerance or Type 2 diabetes \[[@bb0300]\], respectively, our non-diabetic cohorts exhibited significantly lower levels (79 and 148 pg/mL) further confirming the non-diabetic status of our used cohorts. Moreover, we noted that MCP-1 levels in our healthy subjects did not correlate with GDR, nor DLK1 and interestingly, recent data suggest that MCP-1 (and inflammation) is triggered by insulin resistance and not *vice versa* \[[@bb0305]\]. Our findings are in support of the latter, thus regardless of the order of events DLK1 definitely relates to insulin sensitivity at an earlier timepoint than MCP-1. Certainly, more studies are required to establish if Dlk1 may be used together with other parameters as a true early marker/predictor of insulin resistance. Moreover, demonstrating that Dlk1 is positively associated with obesity and insulin resistance might suggest it to be useful in the development of drugs for preventing or treating metabolic syndrome and/or type 2 diabetes.
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